Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1α, in a phase I clinical trial in patients with relapsed/refractory breast cancer

Blood Cells, Molecules and Diseases

Volumn 24, Issue 1, 1998, Pages 14-30

  Broxmeyer, Hal E ^a,b   Orazi, Attilio ^a   Hague, Nancy L ^a,b   Sledge Jr , George W ^a   Rasmussen, Henrik ^c   Gordon, Michael S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

^c British Biotech Inc   (United States)

Author keywords

BB10010; Cell cycle; Chemokine; Clinical trial; Hematopoietic progenitor cells; MIP 1 ; Myelopoiesis

Indexed keywords

CYTARABINE; HYDROXYUREA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; PRIORITY JOURNAL; PROMYELOCYTE; REVIEW;

ARA;

EID: 0031946772     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1998.0167     Document Type: Article

References (52)

1. Broxmeyer H E. Role of cytokines in hematopoiesis. Oppenheim J J, Rossio J L, Gearing A JH. Clinical Aspects of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. 1993;201-206 Oxford University Press, New York.
2. Broxmeyer H E. Role of cytokines in hematopoiesis. Aggarwal B B, Puri R K. Human Cytokines: Their Role in Disease and Therapy. 1995;27-36 Blackwell Scientific Publications, Inc. Cambridge.
3. Broxmeyer H E. Myelosuppressive cytokines and peptides. Whetton T, Gordon T. Blood Cell Biochemistry, Vol. 7: Hemopoietic Growth Factors. 1996;121-150 Plenum, London.
4. Broxmeyer H E. The hematopoietic system: principles of therapy with hematopoietically active cytokines. Ganser A, Hoelzer D. Cytokines in the Treatment of Hematopoietic Failure. 1998;Marcel Dekker, New York.
5. Wolpe S D, Davatelis G, Sherry B. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 167:1988;570-581.
6. Davatelis G, Tekamp-Olson P, Wolpe S D. Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med. 167:1988;1939-1944.
7. Rollins B J. Chemokines. Blood. 90:1997;909-928.
8. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol. 15:1997;675-705.
9. Broxmeyer H E, Sherry B, Lu L. Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2in vitro. J Exp Med. 170:1989;1583-1594.
10. Broxmeyer H E, Sherry B, Lu L. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formationin vitro. Blood. 76:1990;1110-1116.
11. Graham G J, Wright E G, Hewick R. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 344:1990;442-444.
12. Broxmeyer H E, Sherry B, Cooper S. Macrophage inflammatory protein (MIP)-1β abrogates the capacity of MIP-1α to suppress myeloid progenitor cell growth. J Immunol. 147:1991;2586-2594.
13. Bodine D M, Crosier P S, Clark S C. Effects of hematopoietic growth factors on the survival of primitive stem cells in liquid suspension culture. Blood. 78:1991;914-920.
14. Graham G J, Freshney M G, Donaldson D, Pragnell I B. Purification and biochemical characterization of human and murine stem cell inhibitors (SCI). Growth Factors. 7:1992;151-160.
15. Broxmeyer H E, Sherry B, Cooper S. Comparative analysis of the suppressive effects of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. J Immunol. 150:1993;3448-3458.
16. +. Exp Hematol. 23:1995;422-427.
17. Maze R, Sherry B, Kwon B S, Cerami A, Broxmeyer H E. Myelosuppressive effectsin vivo. J Immunol. 149:1992;1004-1009.
18. Clements J M, Craig S, Gearing A JH. Biological and structural properties of MIP-1α expressed in yeast. Cytokine. 4:1992;76-82.
19. Lord B I, Dexter T M, Clements J M, Hunter M A, Gearing A JH. Macrophage inflammatory protein protects multipotent hematopoietic cells from cytotoxic effects of hydroxyureain vivo. Blood. 79:1992;2605-2609.
20. Dunlop D J, Wright E G, Lorimore S. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP-1αin vivo. Blood. 79:1992;2221-2225.
21. Cooper S, Mantel C, Broxmeyer H E. Myelosuppressive effectsin vivo. Exp Hematol. 22:1994;186-193.
22. Lord B I, Woolford L B, Wood L M. Mobilization of early hematopoietic progenitor cells with BB-10010: A genetically engineered variant of human macrophage inflammatory protein-1α Blood. 85:1995;3412-3415.
23. Broxmeyer H E. The cell cycle as therapeutic target. Cancer Invest. 13:1995;617-624.
24. Broxmeyer H E, Vadhan-Raj S. Hemopoietic stem and progenitor cell protection. Marty M. Manual of GM-CSF. 1996;197-207 Blackwell Science, Oxford.
25. Mantel C, Kim Y J, Cooper S, Kwon B, Broxmeyer H E. Polymerization of murine macrophage inflamma-tory protein-1α inactivates its myelosuppressive effectsin vitro. Proc Natl Acad Sci USA. 90:1993;2232-2236.
26. Patel S R, Evans S, Dunne K. Characterization of the quaternary structure and conformational properties of the human stem cell inhibitor protein LD78 in solution. Biochemistry. 32:1993;5466-5471.
27. Graham G J, MacKenzie J, Lowe S. Aggregation of the chemokine MIP-1α is a dynamic and reversible phenomenon. J Biol Chem. 269:1994;4974-4978.
28. Hunter M G, Bawden L, Brotherton D. BB-10010: An active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood. 86:1995;4400-4408.
29. Cooper S, Broxmeyer H E. Measurement of interleukin-3 and other hematopoietic growth factors, such as GM-CSF, G-CSF, M-CSF, erythropoietin and the potent co-stimulating cytokines steel factor and Flt-3 ligand. Coligan J E, Kruisbeek A M, Margulies D H, Shevach E M, Strober W, Coico R. Current Protocols in Immunology. 1996;6.4.1-6.4.12 John Wiley & Sons, Inc. New York.
30. Broxmeyer H E, Benninger L, Cooper S, Hague N, Benjamin R S, Vadhan-Raj S. Effects ofin vivo. Exp Hematol. 23:1995;335-340.
31. Orazi A, Cattoretti G, Shiro R. Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administeredin vivo. Blood. 79:1992;2610-2619.
32. +. Leukaemia. 5:1991;1026-1030.
33. Budke H, Orazi A, Neiman R S, Cattoretti G, John K, Barberis M. Assessment of cell proliferation in paraffin sections of normal bone marrow by the monoclonal antibodies Ki-67 and PCNA. Mod Pathol. 7:1994;860-866.
34. Hall P A, Levison D A, Woods A L. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 162:1990;285-294.
35. Orazi A, Kahsai M, John K, Neiman R S. p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis. Mod Pathol. 9:1996;48-52.
36. Schmitz G G, Walter T, Seibl R, Kessler C. Nonradioactive labeling of oligonucleotidesin vitro. Anal Biochem. 192:1991;222-231.
37. Gavrieli Y, Sherman Y, Ben-Sasson S A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
38. Wijsman J H, Jonker R R, Keijzer R, Van De Velde C JH, Cornelisse C J, Van Dierendonck J H. A new method to detect apoptosis in paraffin sections: In situ end-labeling of fragmented DNA. J Histochem Cytochem. 41:1993;7-12.
39. Laterveer L, Lindley I JD, Hamilton M S, Willemze R, Fibbe W E. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood. 85:1995;2269-2275.
40. Laterveer L, Lindley I JD, Heemskerk D PM. Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8. Blood. 87:1996;781-788.
41. ++. Blood. 87:1996;1644-1653.
42. Roberts A W, Metcalf D. Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. Blood. 86:1995;1600-1605.
43. Siegert W, Serke S. Cytokine mobilized blood CD34-expressing cells are not cycling. Bone Marrow Transplant. 17:1996;467-470.
44. Uchida N, He D, Friera A M. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood. 89:1997;465-472.
45. Gordon M S, McCaskill-Stevens W J, Broxmeyer H E. A phase I trial of subcutaneous (sc) BB-10010 in breast cancer patients (pts) receiving high-dose cyclophosphamide(C). Exp Hematol. 24:1996;1104.
46. Sarris A H, Broxmeyer H E, Wirthmueller U, Karasavvas N, Krueger J, Ravetch J V. Human interferon inducible protein 10: Expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp Med. 178:1993;1127-1132.
47. Broxmeyer H E, Cooper S, Hague N. Human chemokines: enhancement of specific activity and effectsin vitroin vivo. Annals of Hematol. 71:1995;235-246.
48. Broxmeyer H E, Pelus L M, Hromas R. Myelosuppressionin vitroin vivoin vivo. Blood. 90:1997;475a.
49. Broxmeyer H E, Cooper S, Li Z H. Macrophage-stimulating protein, a ligand for the RON . Annals of Hematol. 73:1996;1-9.
50. Hainline L S, Broxmeyer H E, Cooper S. Altered proliferation kinetics, deregulated responsiveness to multiple inhibitory cytokines, and enhanced tumor necrosis factor-α mediated apoptosis in hematopoietic cells from FAC -/-mice. Blood. 1998.
51. Roberts A W, DeLuca E, Begley C G, Basser R, Grigg A P, Metcalf D. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells. 13:1995;512-516.
52. Roberts A W, Foote S, Alexander W S, Scott C, Robb L, Metcalf D. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood. 89:1997;2736-2744.